364793-65-7Relevant articles and documents
Novel quinazoline-containing compound, and intermediate and application thereof
-
, (2021/06/12)
The present invention discloses a quinazoline-containing compound having the formula (IA), (IB) or (IC), or a pharmaceutically acceptable salt or a prodrug molecule thereof. The compound is suitable for use as an Aurora kinase inhibitor and is thus suitable for the treatment of Aurora-mediated diseases characterized by excessive or abnormal cell proliferation, for example, cancer.
Discovery of 4-alkylamino-7-aryl-3-cyanoquinoline LRRK2 kinase inhibitors
Garofalo, Albert W.,Adler, Marc,Aubele, Danielle L.,Brigham, Elizabeth F.,Chian, David,Franzini, Maurizio,Goldbach, Erich,Kwong, Grace T.,Motter, Ruth,Probst, Gary D.,Quinn, Kevin P.,Ruslim, Lany,Sham, Hing L.,Tam, Danny,Tanaka, Pearl,Truong, Anh P.,Ye, Xiaocong M.,Ren, Zhao
, p. 1974 - 1977 (2013/05/08)
Mutations in leucine-rich repeat kinase 2 (LRRK2) are associated with familial Parkinson's disease (PD). The kinase activity of this complex protein is increased by pathogenic mutations. Inhibition of LRRK2 kinase activity has therefore emerged as a promi
Inhibition of Src kinase activity by 4-anilino-7-thienyl-3-quinolinecarbonitriles.
Boschelli, Diane H,Wang, Daniel Y,Ye, Fei,Yamashita, Ayako,Zhang, Nan,Powell, Dennis,Weber, Jennifer,Boschelli, Frank
, p. 2011 - 2014 (2007/10/03)
Based on a screening lead from a yeast-based assay to identify Src family kinase inhibitors, a series of 4-anilino-7-thienyl-3-quinolinecarbonitriles was prepared. When the thiophene ring was substituted with a water-solubilizing group in a 2,5-, 3,5- or 2,4-pattern, potent inhibition of Src kinase activity was observed.